

DOCKET NO.: M00656.70089US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Venkataraman et al.
Serial No.: 10/760,133
Confirmation No.: 7213
Filed: January 16, 2004
For: METHOD FOR IDENTIFYING OR CHARACTERIZING
PROPERTIES OF POLYMERIC UNITS
Examiner: LAU, Tung S.
Art Unit: 2863

MAIL STOP ISSUE FEE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. §1.114. No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

Serial No.: 10/760,133
Conf No.: 7213

- 2 -

Art Unit: 2863

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

	<u>Docket No.</u>	<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>
*	M0656.70095US01	10/967,041	10/14/2004	Pojasek et al.
*	M0656.70095US02	10/966,671	10/14/2004	Pojasek et al.
*	M0656.70101US01	11/107,360	04/15/2005	Berry et al.
*	M0656.70105US03	11/078,915	03/10/2005	Prabhakar et al.
*	M0656.70106US01	11/107,982	04/15/2005	Keiser et al.

*a copy of this reference is not provided as the Office hereby waives the requirement under 37 CFR 1.98(a)(2)(iii) for submitting a copy of each cited U.S. patent application filed after June 30, 2003 and for applications filed before June 30, 2003, or that entered the national stage before June 30, 2003, if they are scanned to Image File Wrapper system and are available on Private PAIR.

The Applicant would like to bring to the Examiner's attention the enclosed search report from a corresponding International or Foreign National Application.

<u>Docket No.</u>	<u>Serial No.</u>	<u>Mailing Date</u>	<u>Type of Communication</u>
M0656.70014WO00	PCT US96/17310	03/12/1997	PCT Search Report
M0656.70046WO00	PCT US99/19841	04/27/2000	PCT Search Report

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

Serial No.: 10/760,133
Conf No.: 7213

- 3 -

Art Unit: 2863


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,


Janice A. Vatland, Ph.D., Reg. No. 52,318
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: M0656.70089US01
Date: May 23, 2005
xNDDx

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 6

APPLICATION NO.: 10/760,133

ATTY. DOCKET NO.: M0656.70089US01

FILING DATE: January 16, 2004

CONFIRMATION NO.: 7213


APPLICANT: Venkataraman et al.

GROUP ART UNIT: 2863

EXAMINER: LAU, Tung S.

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	*	4,281,108		Fussi	07/28/81
	*	4,341,869		Langer, Jr. et al.	07/27/82
	*	4,373,023		Langer et al.	02/08/83
	*	4,396,762		Langer et al.	08/02/83
	*	4,443,545		Langer, Jr. et al.	04/17/84
	*	4,745,105		Griffin et al.	05/17/88
	*	4,757,056		Van Gorp et al.	07/12/88
	*	4,942,156		Foley et al.	07/17/90
	*	4,990,502		Lormeau et al.	02/05/91
	*	5,010,063		Piani et al.	04/23/91
	*	5,039,529		Bergendal et al.	08/13/91
	*	5,106,734		Nielsen	04/21/92
	*	5,152,784		Tsilibary	10/06/92
	*	5,164,378		Conti et al.	11/17/92
	*	5,169,772		Zimmermann et al.	12/08/92
	*	5,204,323		Findlay et al.	04/20/93
	*	5,252,339		Cristofori et al.	10/12/93
	*	5,262,325		Zimmermann et al.	11/16/93
	*	5,290,695		Morikawa et al.	03/01/94
	*	5,338,677		Zimmermann et al.	08/16/94
	*	5,389,539		Sasisekharan et al.	02/14/95
	*	5,474,987		Cohen et al.	12/12/95
	*	5,567,417		Sasisekharan et al.	10/22/96
	*	5,569,600		Sasisekharan et al.	10/29/96
	*	5,576,304		Kakkar et al.	11/19/96
	*	5,599,801		Branellec et al.	02/04/97
	*	5,618,917		Toback et al.	04/08/97
	*	5,619,421		Venkataraman et al.	04/08/97
	*	5,681,733		Su et al.	10/28/97
	*	5,687,090		Chen et al.	11/11/97
	*	5,714,376		Sasisekharan et al.	02/03/98
	*	5,744,515		Clapper	04/28/98
	*	5,752,019		Rigoutosos et al.	05/12/98
	*	5,753,445		Fillit et al.	05/19/98
	*	5,763,427		Weitz et al.	06/09/98
	*	5,795,875		Holme et al.	08/18/98
	*	5,808,021		Holme et al.	09/15/98
	*	5,824,299		Luster et al.	10/20/98



FORM PTO-1449/A and B (Modified)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/760,133

ATTY. DOCKET NO.: M0656.70089US01

FILING DATE: January 16, 2004

CONFIRMATION NO.: 7213

APPLICANT: Venkataraman et al.

GROUP ART UNIT: 2863

EXAMINER: LAU, Tung S.

Sheet 2 of 6

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	*	5,830,726		Sasisekharan et al.	11/03/98
	*	5,856,928		Yan	01/15/99
	*	5,919,693		Su et al.	07/06/99
	*	5,922,358		Doutremepuich et al.	07/13/99
	*	5,997,863		Zimmermann et al.	12/07/99
	*	6,013,628		Skubitz et al.	01/11/00
	*	6,217,863		Godavarti et al.	04/17/01
	*	5,607,859		Biemann et al.	03-04-1997
	*	5,952,653		Covey et al.	09-14-1999
	*	6,268,146	B1	Shultz et al.	07-31-2001
	*	6,291,439	B1	Klock	09-18-2001
	*	6,440,705		Stanton et al.	08-2002
	*	6,597,996	B1	Venkataraman et al.	07-22-2003
	*	6,642,363		Mooney et al.	11-2003
	*	6,653,076		Franza et al.	11-2003
		6,869,789		Liu et al.	03-22-2005
		2002-0122793		Liu et al.	09-05-2002
	*	2002-0128225	A1	Liu et al.	09-12-2002
	*	2002-0169143	A1	Sasisekharan et al.	11-14-2002
	*	2003-0008820	A1	Kwan et al.	01-09-2003
	*	2004-0091471	A1	Myette et al.	05-13-2004
	*	2004-0091472	A1	Pojasek et al.	05-13-2004
	*	2004-0092037	A1	Sasisekharan et al.	05-13-2004
	*	2003-0099628	A1	Liu et al.	05-29-2003
		20050037376	A1	Sasisekharan et al.	02-17-2005
		2003-0191587		Venkataraman et al.	10-09-2003
		2004-0204869		Venkataraman et al.	10-14-2004


FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	*	EP	0 433 225 A1		Ciba-Geigy AG	06/19/91	
	*	EP	0 557 887 A2		Opocrin S.p.A.	09/01/93	
	*	WO	93/08289		Massachusetts Institute of Technology	04/29/93	
	*	WO	93/19096		Cancer Research Campaign Techn. Ltd.	09/30/93	
	*	WO	94/12618	A1	Massachusetts Institute of Technology	06-09-1994	
	*	WO	94/21689		Cancer Research Campaign Techn. Ltd.	09/29/94	

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/760,133	ATTY. DOCKET NO.: M0656.70089US01
FILING DATE: January 16, 2004		CONFIRMATION NO.: 7213	
APPLICANT: Venkataraman et al.			
GROUP ART UNIT: 2863		EXAMINER: LAU, Tung S.	
Sheet	3	of	6

FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	*	WO	95/34635		IBEX Technologies	12/21/95	
	*	WO	97/16556		Massachusetts Institute of Technology	05/09/97	
	*	WO	00/12726	A2	Massachusetts Institute of Technology	03-09-2000	
	*	WO	00/65521	A2	Massachusetts Institute of Technology	11-02-2000	

OTHER ART — NON PATENT LITERATURE DOCUMENTS				
Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	*	Alderman, C. et al., "Continuous Subcutaneous Heparin Infusion for Treatment of Trousseau's Syndrome", <i>Ann Pharmacother</i> , Jul-Aug 1995, 29:(7-8):710-713		
	*	AMEER et al., "A New Approach to Regional Heparinization: Design and Development of a Novel Immobilized Heparinase Device", <i>Blood Purification Meeting Information: The International Conference on Continuous Renal Replacement Therapies</i> , 16(2): 107-108, 1998. ABSTRACT ONLY		
	*	Baumann, U. et al., "Three-dimensional structure of the alkaline protease of <i>Pseudomonas aeruginosa</i> : a two-domain protein with a calcium binding parallel beta roll motif", <i>The EMBO Journal</i> , Vol. 12, No. 9, Pages 3357-3364, 1993		
	*	Bernstein, H. et al., "Immobilized Heparin Lyase System for Blood Deheparinization", <i>Methods in Enzymology</i> , Vol. 137, Pages 515-529, 1988		
	*	Biemann, "Four decades of structure determination by mass spectrometry: from alkaloids to heparin". <i>J Am Soc Mass Spectrom</i> 2002; 13(11):1254-1272.		
	*	Brian Hayes, "Prototeins", <i>American Scientist</i> , Volume 86, May-June 1998, pp. 216-221		
	*	Cardin, A.D. et al., "Molecular Modeling of Protein-Glycosaminoglycan Interactions", <i>Arteriosclerosis</i> , Vol. 9, No. 1, January/February 1989, Pages 21-32		
	*	CLAVERIE et al., "Information Enhancement Methods for Large Scale Sequence Analysis", <i>Computers Chem.</i> , 17(2): 191-201, 1993.		
	*	Cohen, F. E., "The Parallel β Helix of Pectate Lyase C: Something to Sneeze At", <i>Science</i> , Vol. 260, June 4, 1993, Pages 1444-1445		
	*	Comfort, A.R. et al., "Immobilized Enzyme Cellulose Hollow Fibers: III. Physical Properties and <i>In Vitro</i> Biocompatibility", <i>Biotechnology and Bioengineering</i> , Vol. 34, Pages 1383-1390, 1989		
	*	Enriquez-Harris, P. et al., "Growth Factors and the Extracellular Matrix", <i>Meeting Report</i> , Trends in Cell Biology, 1994		
	*	Ernst et al, "Direct evidence for a predominantly exolytic processive mechanism for depolymerization of heparin-like glycosaminoglycans by heparinase" <i>Proc. Natl. Acad. Sci.</i> , Vol. 95. pp. 4182-4197, April 1998		
	*	ERNST et al., "Expression in <i>Escherichia coli</i> , Purification and Characterization of Heparinase I from <i>Flavobacterium heparinum</i> ", <i>Biochem. J.</i> , 315: 589-597, 1996.		
	*	Feingold, D.S. et al., "Conformational aspects of the reaction mechanisms of polysaccharide lyases and epimerases", <i>FEBS Letters</i> , Vol. 223, No. 2, November, 1987, Pages 207-211		
	*	Franklin, M.J. et al., "Pseudomonas Aeruginosa AlgG is a Polymer Level Alginate C5-Mannuronan Epimerase", <i>Journal of Bacteriology</i> , Vol. 176, No. 7, April 1994, Pages 1821-1830		
	*	Gacesa, P., "Alginate-modifying enzymes – A proposed unified mechanism of action for the lyases and epimerases", <i>FEBS Letters</i> , Vol. 212, No. 2, February 1987, Pages 199-202		
	*	Gioldassi et al., "Determination of Phosphorylated and Sulfated Linkage-region Oligosaccharides in Chondroitin / Dermatan and Heparan Sulfate Proteoglycans by High Performance Liquid Chromatography", <i>J. Liq. Chrom. & Rel. Technol.</i> , 22(13): 1997-2007, 1999.		
	*	GODAVARTI et al., "A Comparative Analysis of the Primary Sequences and Characteristics of Heparinases I, II, and III from <i>Flavobacterium heparinum</i> ", <i>Biochemical and Biophysical Research Communications</i> , 229(3): 770-777, 1996.		



FORM PTO-1449/A and B (Modified)


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/760,133 ATTY. DOCKET NO.: M0656.70089US01
FILING DATE: January 16, 2004 CONFIRMATION NO.: 7213
APPLICANT: Venkataraman et al.
GROUP ART UNIT: 2863 EXAMINER: LAU, Tung S.

Sheet 4 of 6

OTHER ART — NON PATENT LITERATURE DOCUMENTS


Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*	GODAVARTI et al., "Heparinase III from <i>Flavobacterium heparinum</i> : Cloning and Recombinant Expression in <i>Escherichia coli</i> ", <i>Biochemical and Biophysical Research Communications</i> , 225(3): 751-758, 1996.	
	*	Godavarti R. et al., "Heparinase I from <i>Flavobacterium heparinum</i> . Identification of a Critical Histidine Residue Essential for Catalysis as Probed by Chemical Modification and Site-Directed Mutagenesis", <i>Biochemistry</i> , Vol. 35, No. 21, 1996, Pages 6846-6852	
	*	GODVARTI et al., "Heparinase I from <i>Flavobacterium heparinum</i> : Role of Positive Charge in Enzymatic Activity", <i>The Journal of Biological Chemistry</i> , 273(1): 248-255, 1998.	
	*	GUERRINI et al., "A Novel Computational Approach to Integrate NMR Spectroscopy and Capillary Electrophoresis for Structure Assignment of Heparin and Heparan Sulfate Oligosaccharides", <i>Glycobiology</i> , 12(11): 713-719, 2002.	
	*	Hart, G.W., "Glycosylation", <i>Current Opinion in Cell Biology</i> , 1992, 4:1017-1023	
	*	Higuchi, R., "Recombinant PCT", <i>PCR Protocols: A Guide to Methods and Applications</i> , Academic Press, Inc., 1990, Pages 177-183	
	*	Huang, J.N. et al., "Low-Molecular-Weight Heparins", <i>Coagulation Disorders</i> , Vol. 12, No. 6, December 1998, Pages 1251-1277	
	*	Jackson, R.L. et al., "Glycosaminoglycans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", <i>Reviews</i> , Vol. 71, No. 2, April 1991, Pages 481-539	
	*	Kakkar, A. et al., "Venous Thromboembolism and Cancer", <i>Baillieres Clin Haematol</i> , September 1998, 11(3):675-687	
	*	KEISER et al., "Direct Isolation and Sequencing of Specific Protein-binding Glycosaminoglycans", <i>Nature Medicine</i> , 7(1): 123-128, 2001.	
	*	Kretsinger, R.H. et al., "Structure and Evolution of Calcium-Modulated Proteins", <i>CRC Critical Reviews in Biochemistry</i> , Vol. 8, Issue 2, July 1980, Pages 119-174	
	*	Leckband, D. et al., "An Approach for the Stable Immobilization of Proteins", <i>Biotechnology and Bioengineering</i> , (1991), Vol. 37, Pages 227-237	
	*	Leckband, D. et al., "Characterization of the Active Site of Heparinase", Abstracts for Papers from the Fourth Chemical Congress of North America, Vol. 202, No. 1, August 1991, New York, Page a56	
	*	Lewin, B., "Cells Obey the Laws of Physics and Chemistry", <i>GENES V</i> , 1994, Page 13	
	*	Linhardt, R.J. et al., "Examination of the Substrate Specificity of Heparin and Heparan Sulfate Lyases", <i>Biochemistry</i> , Vol. 29, No. 10, 1990, Pages 2611-2617	
	*	Linhardt, R.J. et al., "Production and Chemical Processing of Low Molecular Weight Heparins", <i>Seminars in Thrombosis and Hemostasis</i> , Vol. 25, Suppl. 3, 1999, Pages 5-16	
	*	Linhardt, R.J. et al., "Review Polysaccharide Lyases", <i>Applied Biochemistry and Biotechnology</i> , Vol. 12, 1986, Pages 135-176	
	*	LIU, Dongfang, et al., "Dynamic Regulation of Tumor Growth and Metastasis by Heparan Sulfate Glycosaminoglycans", <i>Seminars in Thrombosis and Hemostasis</i> , 28(1): 67-78, 2002.	
	*	LIU, Dongfang, et al., "The Calcium-binding Sites of Heparinase I from <i>Flavobacterium heparinum</i> are Essential for Enzymatic Activity", <i>The Journal of Biological Chemistry</i> , 274(7): 4089-4095, 1999.	
	*	LIU, Dongfang, et al., "Tumor Cell Surface Heparan Sulfate as Cryptic Promoters or Inhibitors of Tumor Growth and Metastasis", <i>PNAS</i> , 99(2): 568-573, 2002.	
	*	LIU, Jian, et al., "Characterization of a Heparan Sulfate Octasaccharide that Binds to Herpes Simplex Virus Type 1 Glycoprotein D", <i>The Journal of Biological Chemistry</i> , 277(36): 33456-33467, 2002.	
	*	LIU, Jian, et al., "Heparan Sulfate D-Glucosaminyl 3-O-Sulfotransferase -3A Sulfates N-Unsubstituted Glucosamine Residues", <i>The Journal of Biological Chemistry</i> , 274(53): 38155-38162, 1999.	
	*	LIU, Jian, et al., "Strategy for the Sequence Analysis of Heparin", <i>Glycobiology</i> , 5(8): 765-774, 1995.	
	*	Lohse, D.L. et al., "Purification and Characterization of Heparin Lyases from <i>Flavobacterium heparinum</i> ", <i>The Journal of Biological Chemistry</i> , Vol. 267, No. 34, Issue of December 5, 1992, Pages 24347-24355	
	*	Lustig, F. et al., "Alternative Splicing Determines the Binding of Platelet-Derived Growth Factor (PDGF-AA) to Glycosaminoglycans", <i>Biochemistry</i> , Vol. 35, No. 37, 1996, Pages 12077-12085	
	*	McLEAN et al., "Enzymic Removal of 2-O-Sulphato- $\Delta_{4,5}$ -Glycuronic Acid Residues from Heparin Oligosaccharides", <i>Proc. of the 7th Int'l. Symposium of Glycoconjugates</i> , p.68-69, 1983.	
	*	MYETTE et al., "Expression in <i>Escherichia coli</i> , Purification and Kinetic Characterization of Human Heparan	



FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/760,133	ATTY. DOCKET NO.: M0656.70089US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: January 16, 2004	CONFIRMATION NO.: 7213
		APPLICANT: Venkataraman et al.	
Sheet 5 of 6		GROUP ART UNIT: 2863	EXAMINER: LAU, Tung S.

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Sulfate 3-O-Sulfotransferase-1", <i>Biochemical and Biophysical Research Communications</i> , 290(4): 1206-1213, 2002.	
	*	MYETTE et al., "Molecular Cloning of the Heparin / Heparan Sulfate Δ4,5 Unsaturated Glycuronidase from <i>Flavobacterium heparinum</i> , its Recombinant Expression in <i>Escherichia coli</i> , and Biochemical Determination of its Unique Substrate Specificity", <i>Biochemistry</i> , 41(23): 7424-7434, 2002.	
	*	MYETTE et al., "The Heparin / Heparan Sulfate 2-O-Sulfatase from <i>Flavobacterium heparinum</i> ", <i>The Journal of Biological Chemistry</i> , 278(14): 12157-12166, 2003.	
	*	POJASEK et al., "Biochemical Characterization of the Chondroitinase B Active Site", <i>The Journal of Biological Chemistry</i> , 277(34): 31179-31186, 2002.	
	*	POJASEK et al., "Histidine 295 and Histidine 510 are Crucial for the Enzymatic Degradation of Heparan Sulfate by Heparinase III", <i>Biochemistry</i> , 39(14): 4012-1019, 2000.	
	*	POJASEK et al., "Recombinant Expression, Purification, and Kinetic Characterization of Chondroitinase AC and Chondroitinase B from <i>Flavobacterium heparinum</i> ", <i>Biochemical and Biophysical Research Communications</i> , 286(2): 343-351, 2001.	
	*	RAMAN et al., "Identification of Structural Motifs and Amino Acids within the Structure of Human Heparan Sulfate 3-O-Sulfotransferase that Mediate Enzymatic Function", <i>Biochemical and Biophysical Research Communications</i> , 290(4): 1214-1219, 2002.	
	*	RAMAN et al., "The Heparin / Heparan Sulfate 2-O-Sulfatase from <i>Flavobacterium heparinum</i> : A Structural and Biochemical Study of the Enzyme Active Site and Saccharide Substrate Specificity", <i>Journal of Biological Chemistry</i> , 278(14): 12167-12174, 2003.	
	*	RHOMBERG et al., "Mass Spectrometric and Capillary Electrophoretic Investigations of the Enzymatic Degradation of Heparin-like Glycosaminoglycans", <i>Proc. Natl. Acad. Sci. USA</i> , 95: 4176-4181, 1998.	
	*	RHOMBERG et al., "Mass Spectrometric Evidence for the Enzymatic Mechanism of the Depolymerization of Heparin-like Glycosaminoglycans by Heparinase II", <i>Proc. Natl. Acad. Sci. USA</i> , 95: 12232-12237, 1998.	
	*	Rhomberg, A et al., "Mass spectrometric sequencing of heparin and heparin sulfate using partial digestion with heparinases", <i>Proc. 45th Annual Conference on Mass Spectrometry Allied Topics</i> , June 1-5, 1997, Palm Springs, CA, page 1026 (Abstract only).	
	*	Rhomberg, AJ, "Mass spectrometric and capillary electrophoretic investigation of heparin, heparinases and related compounds", Ph.D. thesis, MIT (Department of Chemistry), May 22, 1998.	
	*	Rudd et al., "Oligosaccharide Sequencing Technology" <i>Nature</i> , Vol. 388, No. 6638, 10, July 1997, pp. 205-207	
	*	SASISEKHARAN et al., "Heparin and Heparan Sulfate: Biosynthesis, Structure and Function", <i>Current Opinions in Biological Chemistry</i> , 4(6): 626-631, 2000.	
	*	SASISEKHARAN et al., "Roles of Heparan-sulfate Glycosaminoglycans in Cancer", <i>Nature Reviews</i> , 2: 521-528, 2002.	
	*	Sasisekharan, R. et al., "Cloning and expression of heparinase I gene from <i>Flavobacterium heparinum</i> ", <i>Proc Natl Acad Sci USA</i> , Vol. 90, Pages 3660-3664, April 1993	
	*	Sasisekharan, R. et al., "Heparinase I from <i>Flavobacterium heparinum</i> : The Role of the Cysteine Residue in Catalysis as Probed by Chemical Modification and Site-Directed Mutagenesis", <i>Biochemistry</i> , Vol. 34, No. 44, Pages 14441-14448, 1995	
	*	Sasisekharan, R. et al., "Heparinase I from <i>Flavobacterium heparinum</i> ", <i>The Journal of Biological Chemistry</i> , Vol. 271, No. 6, Issue February 9, 1996, Pages 3124-3131	
	*	Sasisekharan, R. et al., "Heparinase inhibits neovascularization", <i>Proc Natl Acad Sci USA</i> , Vol. 91, Pages 1524-1528, February 1994	
	*	SHRIVER et al., "Biochemical Investigations and Mapping of the Calcium-binding Sites of Heparinase I from <i>Flavobacterium heparinum</i> ", <i>The Journal of Biological Chemistry</i> , 274(7): 4082-4088, 1999.	
	*	SHRIVER et al., "Cleavage of the Antithrombin III Binding Site in Heparin by Heparinases and its Implication in the Generation of Low Molecular Weight Heparin", <i>PNAS</i> , 97(19): 10365-10370, 2000.	
	*	SHRIVER et al., "Emerging Views of Heparan Sulfate Glycosaminoglycan Structure / Activity Relationships Modulating Dynamic Biological Functions", <i>TCM</i> , 12(2): 71-77, 2002.	
	*	SHRIVER et al., "Sequencing of 3-O Sulfate Containing Heparin Decasaccharides with a Partial Antithrombin III Binding Site", <i>PNAS</i> , 97(19): 10359-10364, 2000.	
	*	Shriver, Z. et al., "Heparinase II from <i>Flavobacterium heparinum</i> : Role of Histidine Residues in Enzymatic Activity as Probed by Chemical Modification and Site-Directed Mutagenesis", <i>The Journal of Biological</i>	



FORM PTO-1449/A and B (Modified)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet

6

of

6

APPLICATION NO.: 10/760,133

ATTY. DOCKET NO.: M0656.70089US01

FILING DATE: January 16, 2004

CONFIRMATION NO.: 7213

APPLICANT: Venkataraman et al.

GROUP ART UNIT: 2863

EXAMINER: LAU, Tung S.

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
		<i>Chemistry</i> , Vol. 273, No. 17, April 1998, Pages 10160-10167		
	*	Shriver, Z. et al., "Heparinase II from <i>Flavobacterium heparinum</i> : Role of Cysteine in Enzymatic Activity as Probed by Chemical Modification and Site-Directed Mutagenesis," <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 36, Sept 1998, Pages 22904-22912		
	*	SUNDARAM et al., "Rational Design of Low-molecular Weight Heparins with Improved <i>In vivo</i> Activity", <i>PNAS</i> , 100(2): 651-656, 2003.		
	*	Valentine, K.A. et al., "Low-Molecular-Weight Heparin Therapy and Mortality", <i>Seminars in Thrombosis and Hemostasis</i> , Vol. 23, No. 2, 1997, Pages 173-178		
	*	Venkataraman, G et al., "Sequencing complex polysaccharides", <i>Science</i> 15 Oct 1999; 286:537-542.		
	*	YAMADA et al., "Structural Studies on the Bacterial Lyase-resistant Tetrasaccharides Derived from the Antithrombin III-binding Site of Porcine Intestinal Heparin", <i>The Journal of Biological Chemistry</i> , 268(7): 4780-4787, 1993.		
	*	Yan, et al., "Prime Numbers and the Amino Acid Code: Analogy in Coding Properties, <i>J. Theor. Biol.</i> 1991, 151, 333-341.		
	*	Yang, V.C. et al., "Purification and Characterization of Heparinase from <i>Flavobacterium heparinum</i> ", <i>The Journal of Biological Chemistry</i> , Vol. 260, No. 3, February 1985, Pages 1849-1857		
	*	Yoder, M.D. et al., "New Domain Motif: The Structure of Pectate Lyase C., a Secreted Plant Virulence Factor", <i>Science</i> , Vol. 260, Pages 1503-1506, June 4, 1993		
	*	Yoder, M.D. et al., "Unusual structural features in the parallel β -helix in pectate lyases", <i>Structure</i> , December 1993, Vol. 1, No. 4, Pages 241-251		
	*	ZHANG et al., "6-O-Sulfotransferase-1 Represents a Critical Enzyme in the Anticoagulant Heparan Sulfate Biosynthetic Pathway", <i>The Journal of Biological Chemistry</i> , 276(45): 42311-42321, 2001.		
	*	Zhao et al., "Rapid, sensitive structure analysis of oligosaccharides", <i>Proc. Natl. Acad. Sci.</i> , Vol. 94, pp. 1629-1633, March 1997		
	*	Zucharski, L. et al., "Blood Coagulation Activation in Cancer: Challenges for Cancer Treatment", <i>Hamostaseologie</i> , 1995, 15:14-20		

EXAMINER:

DATE CONSIDERED:

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/356,349, filed January 31, 2003, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]